Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Post by McCringleberryon Mar 03, 2017 12:44pm
289 Views
Post# 25927733

Revised Price Target

Revised Price Target

Mackie Research has hiked its price target for Canadian explorer Point Loma Resources Ltd (CVE:PLX) by 10% after the firm announced the completion of the Judy Creek asset acquisition this week.

Reiterating a ‘buy’ rating on the stock, Mackie analyst Bill Newman raised the target for Point Loma to C$1.10 from C$1.00 having increased his risked net asset value estimate to C$1.37 per share from C$1.34.

Newman said the increase reflects the fact that Point Loma only issued 3.35 mln shares to complete the acquisition versus the 4.00 mln that was originally announced due to minor closing adjustments.

The analyst noted that with the completion of the acquisition, Point Loma’s total land position increases by 105,000 acres to over 225,000 net acres.

He also highlighted upcoming production increases to over 900 barrels of oil equivalent per day (boe/d), with a further 450 boe/d expected to be on production this summer.

Newman pointed out that the company plans to drill up to three wells in the third-quarter which he expects to increase production to 1,750 boe/d by the year-end.

Bullboard Posts